- AstraZeneca's (AZN +0.1%) AZD9291 and Clovis Oncology's (CLVS -0.9%) CO-1686 have "blockbuster potential," Leerink's Seamus Fernandez thinks, after considering AZN's ESMO showing. (previous coverage)
- The partial responses in patients with the T790M mutation and "excellent overall tolerability" make Fernandez comfortable with adding $500M to Leerink's AZD-9291 model.
- CLVS is maintained at Outperform with an $88 price target — apparently, there's room for two in the market.
From other sites
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 19, 2015)
at Zacks.com (Mar 18, 2015)
at Nasdaq.com (Feb 17, 2015)
at Benzinga.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs